Thalassemia Treatment Market to be Dominated by Asia Pacific through 2028
Increasing research & development to identify
potential treatment regime for thalassemia is expected to drive the growth of
global thalassemia treatment market in the forecast period, 2024-2028.
According to TechSci Research report, “Thalassemia
Treatment Market –Industry Size, Share, Trends, Opportunity, and Forecast,
2018-2028F”, global thalassemia treatment market is expected to grow during
the forecast period of 2024-2028. This can be ascribed to the increasing
incidences of thalassemia, advancement in technologies, and growing healthcare
expenditure.
Several factors are driving global thalassemia
treatment market, including strategic partnership and collaboration, the
growing burden of thalassemia in endemic regions, and the rising healthcare
spending for availability of effective thalassemic prevention resources. The
development of different therapies for the treatment of thalassemia and
understanding the complex nature of thalassemia are driving the growth of the
market. Finally, the increasing awareness of the importance of early diagnosis
and the potential benefits of a thalassemia medication are contributing to the
growth of the global thalassemia treatment market. These factors are expected
to continue to drive the growth of the global thalassemia treatment market in
the coming years.
Browse over XX market data Figures spread through XX
Pages and an in-depth TOC on "Global Thalassemia Treatment Market"
Global Thalassemia Treatment Market can be
segmented by type and region.
Based on type, global thalassemia treatment market
can be divided into blood transfusions, iron chelation therapy (exjade/jadenu
(deferasirox), ferriprox (deferiprone), desferal (deferoxamine), blood &
bone marrow transplant, and others. The blood transfusion and iron chelation
segment is expected to dominate the global thalassemia treatment market in the
coming years due to the effectiveness of blood transfusions are a common
treatment for thalassemia major, as they help to maintain hemoglobin levels and
prevent complications associated with anemia. Iron chelation therapy is used to
manage iron overload, which is a common complication of thalassemia that can
lead to organ damage. Commonly used iron chelators include deferoxamine
(Desferal), deferiprone (Ferriprox), and deferasirox (Exjade/Jadenu) therefore
the blood transfusion and iron chelation segment is expected to continue
dominating the global thalassemia treatment market in the coming years.
Global thalassemia treatment market is divided into
North America, Europe, Asia Pacific, South America and Middle East &
Africa, based on region. The Asia pacific region is expected to dominate the
global thalassemia treatment market in the coming years due to the high
prevalence of thalassemia in the region. Asia Pacific is considered a major
market for thalassemia treatment due to the high prevalence of thalassemia in
the region. For example, thalassemia is particularly common in Southeast Asia,
where it is estimated that up to 5% of the population may be carriers of the
disease. As a result, there is a significant demand for thalassemia treatments
in the region are expected to drive the growth of the market. Therefore, the Asia
Pacific region is likely to dominate the global thalassemia treatment market in
the coming years.
Major companies operating in global thalassemia
treatment market are:
- Bluebird bio, Inc
- Acceleron Pharma, Inc
- Celgene Corporation
- GlaxoSmithKline plc
- Incyte Corporation
- La Jolla Pharmaceuticals, Inc
- Sanofi S.A.
- Lonza Group Ltd.
- ApoPharma Inc
Download Free Sample Report
Customers can also request for 10% free
customization on this report.
“Global thalassemia treatment market is rapidly
evolving, with significant advancements in vaccine technology and an increasing
number of pharmaceutical companies for medication. The market is dominated by
blood transfusion, which are often used to treat the anemia that results from a
lack of healthy red blood cells. There is a growing focus on early diagnosis,
patient education, research funding, and public policy. Technological
advancements, such as the use of gene therapy and stem cell transplantation,
are driving the development of more effective medications. Additionally, there
is a growing emphasis on the need for medications that are effective against
all thalassemic genetic disorders, including beta thalassemia. The increasing
number of clinical trials and partnerships between public and private sectors
bodes well for the future of the thalassemia treatment market, with several
promising medications candidates currently in advanced stages of development.”
said Mr. Karan Chechi, Research Director with TechSci Research, a research
based global management consulting firm.
“Global Thalassemia Treatment Market- Industry
Size, Share, Trends, Opportunity, and Forecast, 2018-2028F, Segmented By Type (Blood Transfusions, Iron
Chelation Therapy (Exjade/Jadenu (deferasirox), Ferriprox (deferiprone), and
Desferal (deferoxamine)), Blood & Bone Marrow Transplant, and Others), By
Region and Competition,” has evaluated the future growth potential of
global thalassemia treatment market and provides statistics & information
on market size, structure, and future market growth. The report intends to
provide cutting-edge market intelligence and help decision makers take sound
investment decisions. Besides, the report also identifies and analyzes the
emerging trends along with essential drivers, challenges, and opportunities in
global thalassemia treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com